{"ticker": {"uuid": "005b0083-b1af-4012-bff7-8119df5fe230", "symbol": "LUCD", "name": "Lucid Diagnostics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Lucid Diagnostics Inc.'s (LUCD) revenue related to business segments and regions. It indicates that the company has not yet disclosed detailed financial data for business segments and most regional revenue contributions. Currently, the di", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lucd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:09:07", "published_display": "18 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lucid Diagnostics Inc's (LUCD) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization ar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lucd/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:49", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T14:49:04+00:00", "published_display": "16 Jun 2026 14:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxOMV82Sjl0aF9hd3gxUmliWk5Jbk1nb01jcGRva1ByQm5JWVVMUWMzVkxqREwwam9pLWRWUldWa3pNOEJPRGtjSVpaRXlseFBlSVQxM2pSRm92NFBITXdVLVNRRm5fczFEcHFtNC1GTWVaLS1Lekp6dU1BdzJqWEtpZ0J3QmJIY0pxUlhaMGh3RzIyUGZ5SWo5QWJySzFUSnp4cVZTTVlCdjhHMld0dGVxbENub01kb0NfVVhnY2F5YzUwRUM5MU8xNmxoVXE4RTFxRnB2bFY4M1JzYlN0cDZJcDJxUnByS0ZEVC1IMU9CN3RQN0dsM09ucDhsdHdwUTZseklZcEdiWngtUm1GeEdUVUUxVF90SndQaEE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026.", "summary": "Certain stock options of Lucid Diagnostics Inc. are currently subject to a lock-up agreement that concludes on June 9, 2026. This agreement restricts officers and directors from selling or disposing of common stock or convertible securities for a 45-day period, starting April 24,", "url": "https://www.marketscreener.com/news/certain-stock-options-of-lucid-diagnostics-inc-are-subject-to-a-lock-up-agreement-ending-on-9-jun-2-ce7f5dd3dd80f723", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T00:09:31", "published_display": "09 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results", "summary": "Maxim Group reduced its price target on Lucid Diagnostics Inc. (NASDAQ:LUCD) from $3 to $2, while maintaining a Buy rating, following the company's weaker-than-expected first-quarter 2026 revenue report of $1.3 million. Despite the revenue miss and a GAAP net loss of $23.6 millio", "url": "https://www.insidermonkey.com/blog/why-lucid-diagnostics-inc-lucd-faced-a-price-target-reduction-after-q1-results-1773517/", "source_name": "Insider Monkey", "published_at": "2026-06-02T14:05:36", "published_display": "02 Jun 2026 14:05", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD", "summary": "This page provides a comprehensive overview of Lucid Diagnostics Inc. (LUCD) stock, including its latest financial metrics, performance indicators, and recent news. It details the company's stock price, market capitalization, insider ownership, and institutional holdings, alongsi", "url": "https://finviz.com/stock?t=LUCD", "source_name": "Finviz", "published_at": "2026-05-31T22:10:21", "published_display": "31 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD)", "summary": "LUCID DIAGNOSTICS INC (NASDAQ:LUCD) shares are currently trading at $1.05, up 1.94% today. The company has experienced significant price decreases over the past month and year, but analysts expect a substantial price increase of nearly 300% in the next year, along with strong EPS", "url": "https://www.chartmill.com/stock/quote/LUCD/profile", "source_name": "ChartMill", "published_at": "2026-05-29T14:09:36", "published_display": "29 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market", "summary": "Lucid Diagnostics director, Dennis Matheis, purchased 245,000 shares of common stock on the open market at a weighted average price of $1.0011 per share. This transaction increases his direct ownership to 1,033,443 shares. The purchase, reported via a Form 4 SEC filing, indicates", "url": "https://www.stocktitan.net/sec-filings/LUCD/form-4-lucid-diagnostics-inc-insider-trading-activity-0c4fbbb5ec8a.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:20:04", "published_display": "21 May 2026 20:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript", "summary": "Lucid Diagnostics Inc. (NASDAQ:LUCD) reported Q1 2026 earnings, missing expectations with an EPS of $-0.07. The company highlighted performing 3,177 EsoGuard tests, generating $1.3 million in revenue, and strengthening its balance sheet with $16.8 million in proceeds, extending i", "url": "https://www.insidermonkey.com/blog/lucid-diagnostics-inc-nasdaqlucd-q1-2026-earnings-call-transcript-1762807/", "source_name": "Insider Monkey", "published_at": "2026-05-15T12:10:27", "published_display": "15 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)", "summary": "Canaccord Genuity analyst Kyle Mikson CFA has reiterated a Buy rating for Lucid Diagnostics (LUCD) with a price target of $3.00. The company recently reported a quarterly revenue of $1.5 million and a GAAP net loss of $16.27 million. Despite the loss, the analyst consensus mainta", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1954816/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd/", "source_name": "The Globe and Mail", "published_at": "2026-05-15T11:10:27", "published_display": "15 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Earnings Call Balances Progress, Pressure", "summary": "Lucid Diagnostics' Q1 earnings call revealed strong operational progress with EsoGuard test volumes exceeding pre-Medicare targets and an extended cash runway into 2027. However, the company faces significant challenges from slow reimbursement processes, volatile claim adjudicati", "url": "https://www.tipranks.com/news/company-announcements/lucid-diagnostics-earnings-call-balances-progress-pressure", "source_name": "TipRanks", "published_at": "2026-05-15T00:09:52", "published_display": "15 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lucid-diagnostics-inc-lucd-q1-230159293.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:01:59+00:00", "published_display": "14 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/acae1d16-7fd7-3d2c-849a-f18c59652d48/lucid-diagnostics-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-14T21:12:11+00:00", "published_display": "14 May 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics 1Q 2026: Revenue $1.26M, EPS ($0.17) \u2014 10-Q Summary", "summary": "Lucid Diagnostics reported its first-quarter 2026 results, showing revenue of $1.26 million, a 51.7% increase from the prior year, and a reduced loss per share of ($0.17). The company attributed revenue growth to higher EsoGuard test volumes and expanded commercialization efforts", "url": "https://www.tradingview.com/news/tradingview%3Abe29bb7464c55%3A0-lucid-diagnostics-1q-2026-revenue-1-26m-eps-0-17-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T18:10:27", "published_display": "14 May 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/01d7d08b-1a49-33bd-aa80-e7a9a6498fd5/lucid-diagnostics-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-14T17:10:01+00:00", "published_display": "14 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates", "summary": "Lucid Diagnostics Inc. (LUCD) announced its financial results for the first quarter, reporting a loss per share of $0.09. The company also registered revenue of $1.86 million, which fell short of analysts' expectations. This performance indicates a challenging quarter for Lucid D", "url": "https://www.msn.com/en-us/money/topstocks/lucid-diagnostics-inc-lucd-reports-q1-loss-misses-revenue-estimates/ar-AA23chrv", "source_name": "MSN", "published_at": "2026-05-14T16:08:56", "published_display": "14 May 2026 16:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Lucid Diagnostics Q1 2026: Revenue Miss Despite EPS Match", "summary": "Lucid Diagnostics (LUCD) reported Q1 2026 earnings, meeting EPS forecasts at -$0.07 but missing revenue expectations by 8.7% at $1.26 million. The revenue miss was attributed to a conservative revenue recognition policy within a transitional reimbursement environment. Despite the", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-lucid-diagnostics-q1-2026-revenue-miss-despite-eps-match-93CH-4688918", "source_name": "Investing.com", "published_at": "2026-05-14T14:08:56", "published_display": "14 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer test firm ends Q1 with $45M as it targets Medicare coverage", "summary": "Lucid Diagnostics reported Q1 2026 results, including $1.3 million in revenue and processing 3,177 EsoGuard tests, alongside a GAAP net loss of $23.6 million. The company strengthened its balance sheet with an equity offering that brought proforma cash to $45 million, extending i", "url": "https://www.stocktitan.net/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-n2ca57tr02co.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:08:56", "published_display": "14 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "Lucid Diagnostics announced its first-quarter 2026 financial results, processing 3,177 EsoGuard tests and generating $1.3 million in revenue. The company ended the quarter with $45 million in proforma cash, extending its runway into 2027, and emphasized that securing Medicare cov", "url": "https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results-302771862.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:08:55", "published_display": "14 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) narrows loss and extends cash runway into 2027", "summary": "Lucid Diagnostics reported its Q1 2026 financial results, showing a GAAP net loss of $13.9 million and processing 3,177 EsoGuard tests, generating $1.3 million in revenue. The company successfully executed an underwritten public offering, netting $17 million, which extends its pr", "url": "https://www.stocktitan.net/sec-filings/LUCD/8-k-lucid-diagnostics-inc-reports-material-event-9cc50e7235d5.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:08:55", "published_display": "14 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCID DIAGNOSTICS ($LUCD) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPYnI0RmEyTllrSzdteWJGelh5VndzNFdLOFhyd3Z6UXRaTVVYR3dIdXppOTBPTVhWWkF4QkNIRTNXWG1EcTdTaTJnTTdfMEVtLWFrRmt2WEc1NTVKOFRqTTZ0SF9OMUxHQ0lyVEptM0xhQnlQZ1ZRQU9URFk2NzB0V21Hc1Q1TUQtcklnM2lPSndyTlUz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD: Q1 2026 saw higher revenue but continued losses, with future viability hinging on reimbursement and capital", "summary": "Lucid Diagnostics Inc. (LUCD) reported increased revenue of $1.3M in Q1 2026, but also a net loss of $23.6M due to high costs. Despite boosting cash reserves to $27.9M with an April offering, the company's long-term survival is uncertain without more reimbursement options or addi", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3324092:0-lucd-q1-2026-saw-higher-revenue-but-continued-losses-with-future-viability-hinging-on-reimbursement-and-capital/", "source_name": "TradingView", "published_at": "2026-05-13T20:40:02", "published_display": "13 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) grows Q1 revenue but flags going-concern risk", "summary": "Lucid Diagnostics (NASDAQ: LUCD) reported increased Q1 2026 revenue of $1.3 million, up from $0.8 million year-over-year, driven by its EsoGuard test. However, the company continues to face significant financial challenges, posting a net loss of $23.6 million and disclosing \"subs", "url": "https://www.stocktitan.net/sec-filings/LUCD/10-q-lucid-diagnostics-inc-quarterly-earnings-report-f3e71e28fea0.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:02", "published_display": "13 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (Nasdaq:LUCD) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of Lucid Diagnostics (Nasdaq:LUCD), a medical diagnostics technology company. It covers financial performance, future growth prospects, risks, and recent news, highlighting the company's EsoGuard Esophageal DNA Test for early ca", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics", "source_name": "Simply Wall Street", "published_at": "2026-05-13T18:10:27", "published_display": "13 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Report Preview: What To Look For", "summary": "", "url": "https://finance.yahoo.com/news/lucid-diagnostics-inc-lucd-q1-131906047.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T13:19:06+00:00", "published_display": "13 May 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates", "summary": "Lucid Diagnostics Inc. (LUCD) reported a narrower-than-expected loss of 15 cents per share for the fourth quarter, surpassing the Zacks Consensus Estimate of a 19-cent loss. The company also beat revenue estimates, reporting $1.16 million compared to the anticipated $0.94 million", "url": "https://www.msn.com/en-us/money/other/lucid-diagnostics-inc-lucd-reports-q4-loss-beats-revenue-estimates/ar-AA1ZseRq?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-05-06T04:39:17", "published_display": "06 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026", "summary": "Lucid Diagnostics Inc. (Nasdaq: LUCD) announced it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. Chairman and CEO Lishan Aklog, M.D., will provide a business update, while CFO Dennis McGrath will discuss the Company's first-quar", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lucid-diagnostics-hold-first-quarter-123100523.html", "source_name": "Market source", "published_at": "2026-05-01T01:09:28", "published_display": "01 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) seeks big share increase in 2026 proxy", "summary": "Lucid Diagnostics (NASDAQ: LUCD) has filed a proxy statement for its June 24, 2026, annual meeting, seeking stockholder approval to increase authorized common shares from 300 million to 400 million. This increase aims to support future financings, equity awards, and conversions, ", "url": "https://www.stocktitan.net/sec-filings/LUCD/def-14a-lucid-diagnostics-inc-definitive-proxy-statement-ceca75a7191f.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:10:10", "published_display": "30 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG", "summary": "BTIG reiterated its Buy rating on Lucid Diagnostics (LUCD) as the company is close to securing Medicare coverage for its EsoGuard test. CMS has established a new G-code for esophageal cellular \u09b8\u0982\u0997\u09cd\u09b0\u09b9 tests, which may accelerate the approval process for EsoGuard.", "url": "https://www.msn.com/en-us/money/savingandinvesting/lucid-nearing-medicare-coverage-for-esoguard-test-maintain-at-buy-btig/ar-AA1Jse8c?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c", "source_name": "MSN", "published_at": "2026-04-27T03:41:03", "published_display": "27 Apr 2026 03:41", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (LUCD) CMO reports 650K restricted shares and 100K options", "summary": "Lucid Diagnostics Chief Medical Officer, Victoria Lee Tou-ho, has filed an amended Form 3, disclosing her equity holdings. The report details 650,000 restricted shares of Common Stock with varying vesting dates through May 2029, dependent on service requirements. Additionally, sh", "url": "https://www.stocktitan.net/sec-filings/LUCD/form-3-a-lucid-diagnostics-inc-amended-initial-statement-of-beneficia-0f15d52a95c1.html", "source_name": "Stock Titan", "published_at": "2026-04-24T21:15:52", "published_display": "24 Apr 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) closes $18M underwritten stock sale", "summary": "Lucid Diagnostics Inc. (NASDAQ: LUCD) has announced the closing of an underwritten public offering, generating approximately $18 million in gross proceeds from the sale of 18,000,000 shares of common stock at $1.00 per share. The net proceeds, estimated at $16.8 million, will be ", "url": "https://www.stocktitan.net/sec-filings/LUCD/8-k-lucid-diagnostics-inc-reports-material-event-7964b651b0b0.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:39:52", "published_display": "24 Apr 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics closes $18M underwritten offering, issues 18M shares at $1.00", "summary": "Lucid Diagnostics (LUCD) successfully closed an underwritten offering, selling 18 million common shares at $1.00 each to raise approximately $18 million in gross proceeds. Net proceeds of about $16.8 million are earmarked for working capital and general corporate purposes. The of", "url": "https://www.tradingview.com/news/tradingview:b3e6d93a865c3:0-lucid-diagnostics-closes-18m-underwritten-offering-issues-18m-shares-at-1-00/", "source_name": "TradingView", "published_at": "2026-04-24T20:09:18", "published_display": "24 Apr 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by a $15M investor, Lucid closes $18M share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbGx5eHRKNWMwb3ZzOXJXZzdsckhkQk9MMlBIVkF0bTN0V0Znb0lWNTVwYU9sT2NndXdfaS1vZlZ0NDJsak1zTlpZdXNBa1NKRnNxWUkyMG01M1VKMHRFRmNvN3ozMVBpYW5Hb0FrREJ5LVRvM1p1QTh1NUpza2s5Tzc5czFSQWl0bFVmOHAtQ1hZdjBhVEZPWXFpX3F5MUtLSFczbW9iQm9NNUhtMnVXUFoxUGRpNUxi?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNdGx5U3d2SVJwMklKU1ZHRkFtMDRyNmUzNTUtNGpUc19lSXkteVdBWDZaT1RiWGxsdTNBb3NsQ0FDbUVfWUk3cGxGQk5lOUdqV0w5VjNQUTRNWG9CcnpwV1F5d3hBc0pMb25VNlExRHdHMFl2c2tUSndXRGMyaTBnWGp4M29rNkNyZURlRzNEMm43WUh0UUdUbkVkekp4T215V1ZzLXVMTHNvVFoyRzlPNVJ6R21NRFVRNnpuVTZSUHZyUl9vd213Z3pEeEo?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (Nasdaq: LUCD) prices $18M underwritten stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOUTV1XzY3Q29hOThsY2ZJYmhpRlBKcHZYbDFiMWpDM0U3UHo0bUtQQ3NHLW5HMFVzbFhwNnhUWkpWNjRYdXJsSGJxTVFXVGhoT1lGd0lMVHBoQXV1Y2M1OGp6c3hodHYxcHFUdTV0TTdqSF9zY2M0N2xkRU94SWxOVW5Yd2oyT0JzUXZsVEtxTnNHU1J2ZGJRRmlKeC1XazQ4ZnBoai16ZEI2MkVhcWI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $15M anchor investor backs Lucid\u2019s 18M-share stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVWZkSGR3LUY5VXpmc3dPRExoWTQ2cnBSbHNNbUpxMHJzYWdHR29pTkFfbGFRZFp0eVJCT0hGNFFpYzFtSDVDQzZVQzJFN2U4elptQ3YybEtxV2JQemxrRjd6YWtPSjR5RFhVYnVVZTctZjAwWUpSUVZqUTE2cG1scDJzLUNBNWJaSFgtUFJjWGxuazY5OWExQk1ydEQxTmktcEt6MVpKUzY3NXN5MlNFdVp0OG51ODFndWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Prices $18 Million Underwritten Offering at $1 Per Share With Canaccord and BTIG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxOb1FUaWpwVVVYWFRhY1B4X0otZEZYSjU1UzlWUWRYd3gyc0FnOUpWck93d0c0WTRWMGJyTUxQaldfbnV5MUFCLUlCMUE3bDEwcEt2OVFMN3N6T3BXbjJoOUg0dkg3a0VSWUloeXVsX2RpTTU4MGpvTS14LWp1TmdsWDFpRkVZRmZodkhqMWFTY3h4Tkd2VElGenZPU2VneVI2Q21tWnUzTlF5SU9OeDVKMXFpcDZHZHFEdUdJN3lKTnB4UTJxd2xGZkF2RzQ4ME11NzJLaGh2Ni1FVWtjYy1jMVNibDJ4QWd1TUJKaHNRaw?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BTIG reiterates Lucid Diagnostics stock rating on Q4 beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWS1Xem8wWkVNZk50OE51bnVvUnNicmtPemtNZjNNUDhKNEhyTU5UY3VsS1VQdFd3VXl5QmZIejhRNlhaY3pUNzFDVGx2NHlPREdrN0tMbDJCM1pkT0hkcVdOSUx2UjZqTERnV2VnT2xLc3dnWlZIOXJpa29BcGFkZHNMLS1ZWkRkQlJweWVwaU1sZkZqZGx5S1dxcFNxT0d6d2hMX1hpU21qSzdoYWptR1dhaXRvbnNn?oc=5", "source_name": "Investing.com", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNaXgtTEYyZmZQcVV5c2pwX0Q1b1JETHdBaU5PdlI2eXEyejlGYUlQenZPdzdCa29sYVF4WWpYUUlaSjZINTRQTGNkSnROS3p1T0I2YkJuMDJwcGFrd04zUXZ0c3NVb2g4blZBaEcySDZ2V2p4c3JXVGY5Y19rVTgtTUJ1dUR2RDJFMHNDTTJwTXpFMzBWWHZOZkEyOWExbGJHTWl3eVJhMUtranNlLXMxOFNHTDFiRmN1cDhCbW5OdzR5MktyNl9oanBzNGw2NTBDMzhZWVA0alVPYlVQWUdSYzhLNVcwUTdleHZScWFxUUwxeE54?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTnpEZEE3YUJUaG05TXdrWGh4T0x0NEUzTU9lMDNBZWNkcU52RWdwSU50QkI4RXhYSlBxdGJucXZOMERRY1ZFMU4yZWVFTW9KY0VBMWY4eVJpVFpiaDlsQVdUbkNkZEMzUGJmSXNfTWZCNDNTT2tsNERrLS11Y1M3dDRveXlydUZaWGxqTHVZcmZTMGlkXzlWN2xFLTJSS28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & Supplies - Imaging, Diagnostics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxORnRwNHkwQmJ3Nl9famF1aktWdDdLV2ZfNjFCVm9WSFJrQTRSMURQUEJrMGtZUTFiVEtZWGxyUWwwai04Zk4wZ2pTWXFsLUozTzR2Ykd5UUREenZmSTRWdzJPODNONWFCWUVoVlBuTmtVSnpWQXFOVEVMdWNDLWNfRnRqRWdweElVS2pabQ?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Specialty Stocks\u2019 Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQcXUxeEZpRzE0aXJ0RVlrVXZMdF9pSEV3VTROeDNWdjNZZWVDNVhKZU9BRFpIOWlZYzJrU1RZVzFDLUZhRDBjY0pBdVB2YVJUNVZvZEhubmd1OXlobFJaUWxVbUtlVEFwdWNVQnRqMDBHbEFubzBpczN1Zi1mN0xFbC1pTHpqZzA?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q3 Earnings: Inspire Medical Systems (NYSE:INSP) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOekhIMGs0UXlrdHhudkYzRWhSXzBNazdMLXBSTnd5dEFTZDR3MkdBc1AtNUNrcmp4Z1IxNVBuZVJJejdkdjdwT1Zoc0NudGMxVGNjRGxaUGVrYncxekxMNWV5RGlNNjZWUW9vdzdwaVRtTlMzcFl0MWRZNDlTY0xWWkNteE9fTU9LMm5aX1VuSll2UTNONzRqNnVpYXRvbDVIX1lXaGJMV3JKZFltUTVPNVpUc2Q0MHdYVUUydmZUMVo4dDIzLUxjZk53c1J1bDcxTXJWa0VNZXdJanZfbUVHcmgwamRwaGJyc1pXeGhtZ1dnaTJMN2JCeHlJLUFCZXRaVFhaUHozVi1wRlQ1dkE?oc=5", "source_name": "StockStory", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard\u00ae", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZUtIMy1XcDZqMVAwRER3VHU4cHE1MlhMMFZrdnp2Ty1YX3JwRXFJdzZfYk1lUUx1UHRUY3BOcVNRbWQ2SUR0WU9yNWtiazBNZ3U3cmZ5aXNVNXFwdVczUXNkZ3huMWVJckJKTTFTODdpU1BqVUZ1eTJleG14S3U0SklKaklFMURLQzJRZXZXN0xLZUFzZFlLcWwtZ1NtWEwwUVFzQjFBc3pEc3pfM3NqcnFJZmR4d09mN3UxMHpHbnBuOGJmQzg0NHczRnBkVVdNZHRZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PAVmed-unit Lucid Diagnostics spikes on VA contract (LUCD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOVGkyQno5anU4TkRPQW03WWdXT1UtaWcxX3NGdnFVZlFINHE3clRtb3hpTFlxQVhxd1ZzNVd2bWNoY1NXblNQNTlCMXRRVkp4azh3TlkxV2Znb1BNWEw1Qm1fMHhnQ05RVXlXQTJYX01VendtNVZPc2FwUlIzbGExckJjbHhjNmM3cDJVUUYxdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VA taps Lucid's EsoGuard cancer test, opening access for 9M veterans", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOclVlT1FYNXBGcW5ROFhMX2luYnF6eEhHZmpjNkYzMG5oT3VtYllFeS0zUWM4YWFhRHQtNUFUQUdiS1JuTmZ2VktZa3o5SHJoMFY1aWphNkVFa3JyRmpBM1NHa0dlYTcyVXVwRklUamgyWVFrWTFyT3VVeWRUUzQta2hpRHFFX0VBMUVFNllGTllveHVROWJpb0EtMDZlX1ZzS2dlSF9EaFk4VFpQVkFfLU9NQXFFZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Lucid Diagnostics (LUCD) Declined in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOcl81cGZ5STlSWFl2dGlBNEZjOVBJUThOeHFtb21JN0RuamhRczdSR2pOS0Qtd3NiSjFTTVhEQmctN1F0U2FUZDdiR1ZFQVlQdE0ydmhMMURyRUlUa2YtVEtNMDI3bWlrV29RTGpkRUQtMW5oUVFWMlRpVENBNno4UHBmVUlyN2FL?oc=5", "source_name": "Market source", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30%", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQa2pZaTdoTFg0V05OaFVGWEZ5Y1V6QXh4OVlhZ3M5ckk5ajJmdWtJanJBQml6LWg4ejd3WkNVZkV5REtCRl9oTjgwRUZtckFEdk95QXM3YnNRUXdEMW41UEtMSHJleEFVMmxvOGlmVzVQc3VvZGxITXF0clEwY3p0bVNFSkZlUQ?oc=5", "source_name": "Market source", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q3 Earnings Outperformers: Enovis (NYSE:ENOV) And The Rest Of The Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPTFZqejZjVDBJV2huRzViQmxXeEQ5SWc3aC1NN0RITkxhdlpCYjRSa0FUTDdtRXJzcWQ5UnJlQXY2QW11cGpKMGdGVGFiZGhrcm1UVnA0YUprNG1uQktqWnU0Ny1WTTcxcTIxZkJLNHJUcEU0aVl3Um8xTzhqQW5uREI1NU5qYUZTbkV4M3JPMzFvbW5TamdZcnphRlpubTNvOEJHSU9mcUhXdkpEVmJtNXRCUEtYTHZmT2NIbmQ1Wmpsb3doeFQxUERIQk5zYjJ0Vi1FR1ZDZ3lXdzlJSWRfa0VIR0xTYnJTWjRUUzJNblVyTld3Qm9B?oc=5", "source_name": "StockStory", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Lucid Diagnostics Inc.'s (LUCD) revenue related to business segments and regions. It indicates that the company has not yet disclosed detailed financial data for business segments and most regional revenue contributions. Currently, the di", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lucd/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:09:07", "published_display": "18 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Lucid Diagnostics Inc's (LUCD) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and has no recorded stock split events. The current stock price and market capitalization ar", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lucd/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:49", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Stock Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2026.", "summary": "Certain stock options of Lucid Diagnostics Inc. are currently subject to a lock-up agreement that concludes on June 9, 2026. This agreement restricts officers and directors from selling or disposing of common stock or convertible securities for a 45-day period, starting April 24,", "url": "https://www.marketscreener.com/news/certain-stock-options-of-lucid-diagnostics-inc-are-subject-to-a-lock-up-agreement-ending-on-9-jun-2-ce7f5dd3dd80f723", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T00:09:31", "published_display": "09 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results", "summary": "Maxim Group reduced its price target on Lucid Diagnostics Inc. (NASDAQ:LUCD) from $3 to $2, while maintaining a Buy rating, following the company's weaker-than-expected first-quarter 2026 revenue report of $1.3 million. Despite the revenue miss and a GAAP net loss of $23.6 millio", "url": "https://www.insidermonkey.com/blog/why-lucid-diagnostics-inc-lucd-faced-a-price-target-reduction-after-q1-results-1773517/", "source_name": "Insider Monkey", "published_at": "2026-06-02T14:05:36", "published_display": "02 Jun 2026 14:05", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD", "summary": "This page provides a comprehensive overview of Lucid Diagnostics Inc. (LUCD) stock, including its latest financial metrics, performance indicators, and recent news. It details the company's stock price, market capitalization, insider ownership, and institutional holdings, alongsi", "url": "https://finviz.com/stock?t=LUCD", "source_name": "Finviz", "published_at": "2026-05-31T22:10:21", "published_display": "31 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD Stock Price, Quote & Chart | LUCID DIAGNOSTICS INC (NASDAQ:LUCD)", "summary": "LUCID DIAGNOSTICS INC (NASDAQ:LUCD) shares are currently trading at $1.05, up 1.94% today. The company has experienced significant price decreases over the past month and year, but analysts expect a substantial price increase of nearly 300% in the next year, along with strong EPS", "url": "https://www.chartmill.com/stock/quote/LUCD/profile", "source_name": "ChartMill", "published_at": "2026-05-29T14:09:36", "published_display": "29 May 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market", "summary": "Lucid Diagnostics director, Dennis Matheis, purchased 245,000 shares of common stock on the open market at a weighted average price of $1.0011 per share. This transaction increases his direct ownership to 1,033,443 shares. The purchase, reported via a Form 4 SEC filing, indicates", "url": "https://www.stocktitan.net/sec-filings/LUCD/form-4-lucid-diagnostics-inc-insider-trading-activity-0c4fbbb5ec8a.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:20:04", "published_display": "21 May 2026 20:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2026 Earnings Call Transcript", "summary": "Lucid Diagnostics Inc. (NASDAQ:LUCD) reported Q1 2026 earnings, missing expectations with an EPS of $-0.07. The company highlighted performing 3,177 EsoGuard tests, generating $1.3 million in revenue, and strengthening its balance sheet with $16.8 million in proceeds, extending i", "url": "https://www.insidermonkey.com/blog/lucid-diagnostics-inc-nasdaqlucd-q1-2026-earnings-call-transcript-1762807/", "source_name": "Insider Monkey", "published_at": "2026-05-15T12:10:27", "published_display": "15 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)", "summary": "Canaccord Genuity analyst Kyle Mikson CFA has reiterated a Buy rating for Lucid Diagnostics (LUCD) with a price target of $3.00. The company recently reported a quarterly revenue of $1.5 million and a GAAP net loss of $16.27 million. Despite the loss, the analyst consensus mainta", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1954816/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd/", "source_name": "The Globe and Mail", "published_at": "2026-05-15T11:10:27", "published_display": "15 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Earnings Call Balances Progress, Pressure", "summary": "Lucid Diagnostics' Q1 earnings call revealed strong operational progress with EsoGuard test volumes exceeding pre-Medicare targets and an extended cash runway into 2027. However, the company faces significant challenges from slow reimbursement processes, volatile claim adjudicati", "url": "https://www.tipranks.com/news/company-announcements/lucid-diagnostics-earnings-call-balances-progress-pressure", "source_name": "TipRanks", "published_at": "2026-05-15T00:09:52", "published_display": "15 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lucid-diagnostics-inc-lucd-q1-230159293.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:01:59+00:00", "published_display": "14 May 2026 23:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/acae1d16-7fd7-3d2c-849a-f18c59652d48/lucid-diagnostics-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-14T21:12:11+00:00", "published_display": "14 May 2026 21:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics 1Q 2026: Revenue $1.26M, EPS ($0.17) \u2014 10-Q Summary", "summary": "Lucid Diagnostics reported its first-quarter 2026 results, showing revenue of $1.26 million, a 51.7% increase from the prior year, and a reduced loss per share of ($0.17). The company attributed revenue growth to higher EsoGuard test volumes and expanded commercialization efforts", "url": "https://www.tradingview.com/news/tradingview%3Abe29bb7464c55%3A0-lucid-diagnostics-1q-2026-revenue-1-26m-eps-0-17-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T18:10:27", "published_display": "14 May 2026 18:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/01d7d08b-1a49-33bd-aa80-e7a9a6498fd5/lucid-diagnostics-q1-earnings.html", "source_name": "MarketBeat", "published_at": "2026-05-14T17:10:01+00:00", "published_display": "14 May 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) reports Q1 loss, misses revenue estimates", "summary": "Lucid Diagnostics Inc. (LUCD) announced its financial results for the first quarter, reporting a loss per share of $0.09. The company also registered revenue of $1.86 million, which fell short of analysts' expectations. This performance indicates a challenging quarter for Lucid D", "url": "https://www.msn.com/en-us/money/topstocks/lucid-diagnostics-inc-lucd-reports-q1-loss-misses-revenue-estimates/ar-AA23chrv", "source_name": "MSN", "published_at": "2026-05-14T16:08:56", "published_display": "14 May 2026 16:08", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Lucid Diagnostics Q1 2026: Revenue Miss Despite EPS Match", "summary": "Lucid Diagnostics (LUCD) reported Q1 2026 earnings, meeting EPS forecasts at -$0.07 but missing revenue expectations by 8.7% at $1.26 million. The revenue miss was attributed to a conservative revenue recognition policy within a transitional reimbursement environment. Despite the", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-lucid-diagnostics-q1-2026-revenue-miss-despite-eps-match-93CH-4688918", "source_name": "Investing.com", "published_at": "2026-05-14T14:08:56", "published_display": "14 May 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer test firm ends Q1 with $45M as it targets Medicare coverage", "summary": "Lucid Diagnostics reported Q1 2026 results, including $1.3 million in revenue and processing 3,177 EsoGuard tests, alongside a GAAP net loss of $23.6 million. The company strengthened its balance sheet with an equity offering that brought proforma cash to $45 million, extending i", "url": "https://www.stocktitan.net/news/LUCD/lucid-diagnostics-provides-business-update-and-reports-first-quarter-n2ca57tr02co.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:08:56", "published_display": "14 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "Lucid Diagnostics announced its first-quarter 2026 financial results, processing 3,177 EsoGuard tests and generating $1.3 million in revenue. The company ended the quarter with $45 million in proforma cash, extending its runway into 2027, and emphasized that securing Medicare cov", "url": "https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results-302771862.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:08:55", "published_display": "14 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) narrows loss and extends cash runway into 2027", "summary": "Lucid Diagnostics reported its Q1 2026 financial results, showing a GAAP net loss of $13.9 million and processing 3,177 EsoGuard tests, generating $1.3 million in revenue. The company successfully executed an underwritten public offering, netting $17 million, which extends its pr", "url": "https://www.stocktitan.net/sec-filings/LUCD/8-k-lucid-diagnostics-inc-reports-material-event-9cc50e7235d5.html", "source_name": "Stock Titan", "published_at": "2026-05-14T12:08:55", "published_display": "14 May 2026 12:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCID DIAGNOSTICS ($LUCD) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPYnI0RmEyTllrSzdteWJGelh5VndzNFdLOFhyd3Z6UXRaTVVYR3dIdXppOTBPTVhWWkF4QkNIRTNXWG1EcTdTaTJnTTdfMEVtLWFrRmt2WEc1NTVKOFRqTTZ0SF9OMUxHQ0lyVEptM0xhQnlQZ1ZRQU9URFk2NzB0V21Hc1Q1TUQtcklnM2lPSndyTlUz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LUCD: Q1 2026 saw higher revenue but continued losses, with future viability hinging on reimbursement and capital", "summary": "Lucid Diagnostics Inc. (LUCD) reported increased revenue of $1.3M in Q1 2026, but also a net loss of $23.6M due to high costs. Despite boosting cash reserves to $27.9M with an April offering, the company's long-term survival is uncertain without more reimbursement options or addi", "url": "https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3324092:0-lucd-q1-2026-saw-higher-revenue-but-continued-losses-with-future-viability-hinging-on-reimbursement-and-capital/", "source_name": "TradingView", "published_at": "2026-05-13T20:40:02", "published_display": "13 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) grows Q1 revenue but flags going-concern risk", "summary": "Lucid Diagnostics (NASDAQ: LUCD) reported increased Q1 2026 revenue of $1.3 million, up from $0.8 million year-over-year, driven by its EsoGuard test. However, the company continues to face significant financial challenges, posting a net loss of $23.6 million and disclosing \"subs", "url": "https://www.stocktitan.net/sec-filings/LUCD/10-q-lucid-diagnostics-inc-quarterly-earnings-report-f3e71e28fea0.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:02", "published_display": "13 May 2026 20:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (Nasdaq:LUCD) - Stock Analysis", "summary": "This report provides a comprehensive stock analysis of Lucid Diagnostics (Nasdaq:LUCD), a medical diagnostics technology company. It covers financial performance, future growth prospects, risks, and recent news, highlighting the company's EsoGuard Esophageal DNA Test for early ca", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics", "source_name": "Simply Wall Street", "published_at": "2026-05-13T18:10:27", "published_display": "13 May 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Report Preview: What To Look For", "summary": "", "url": "https://finance.yahoo.com/news/lucid-diagnostics-inc-lucd-q1-131906047.html", "source_name": "GuruFocus.com", "published_at": "2026-05-13T13:19:06+00:00", "published_display": "13 May 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates", "summary": "Lucid Diagnostics Inc. (LUCD) reported a narrower-than-expected loss of 15 cents per share for the fourth quarter, surpassing the Zacks Consensus Estimate of a 19-cent loss. The company also beat revenue estimates, reporting $1.16 million compared to the anticipated $0.94 million", "url": "https://www.msn.com/en-us/money/other/lucid-diagnostics-inc-lucd-reports-q4-loss-beats-revenue-estimates/ar-AA1ZseRq?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-05-06T04:39:17", "published_display": "06 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026", "summary": "Lucid Diagnostics Inc. (Nasdaq: LUCD) announced it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. Chairman and CEO Lishan Aklog, M.D., will provide a business update, while CFO Dennis McGrath will discuss the Company's first-quar", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lucid-diagnostics-hold-first-quarter-123100523.html", "source_name": "Market source", "published_at": "2026-05-01T01:09:28", "published_display": "01 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) seeks big share increase in 2026 proxy", "summary": "Lucid Diagnostics (NASDAQ: LUCD) has filed a proxy statement for its June 24, 2026, annual meeting, seeking stockholder approval to increase authorized common shares from 300 million to 400 million. This increase aims to support future financings, equity awards, and conversions, ", "url": "https://www.stocktitan.net/sec-filings/LUCD/def-14a-lucid-diagnostics-inc-definitive-proxy-statement-ceca75a7191f.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:10:10", "published_display": "30 Apr 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG", "summary": "BTIG reiterated its Buy rating on Lucid Diagnostics (LUCD) as the company is close to securing Medicare coverage for its EsoGuard test. CMS has established a new G-code for esophageal cellular \u09b8\u0982\u0997\u09cd\u09b0\u09b9 tests, which may accelerate the approval process for EsoGuard.", "url": "https://www.msn.com/en-us/money/savingandinvesting/lucid-nearing-medicare-coverage-for-esoguard-test-maintain-at-buy-btig/ar-AA1Jse8c?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c", "source_name": "MSN", "published_at": "2026-04-27T03:41:03", "published_display": "27 Apr 2026 03:41", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (LUCD) CMO reports 650K restricted shares and 100K options", "summary": "Lucid Diagnostics Chief Medical Officer, Victoria Lee Tou-ho, has filed an amended Form 3, disclosing her equity holdings. The report details 650,000 restricted shares of Common Stock with varying vesting dates through May 2029, dependent on service requirements. Additionally, sh", "url": "https://www.stocktitan.net/sec-filings/LUCD/form-3-a-lucid-diagnostics-inc-amended-initial-statement-of-beneficia-0f15d52a95c1.html", "source_name": "Stock Titan", "published_at": "2026-04-24T21:15:52", "published_display": "24 Apr 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (NASDAQ: LUCD) closes $18M underwritten stock sale", "summary": "Lucid Diagnostics Inc. (NASDAQ: LUCD) has announced the closing of an underwritten public offering, generating approximately $18 million in gross proceeds from the sale of 18,000,000 shares of common stock at $1.00 per share. The net proceeds, estimated at $16.8 million, will be ", "url": "https://www.stocktitan.net/sec-filings/LUCD/8-k-lucid-diagnostics-inc-reports-material-event-7964b651b0b0.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:39:52", "published_display": "24 Apr 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics closes $18M underwritten offering, issues 18M shares at $1.00", "summary": "Lucid Diagnostics (LUCD) successfully closed an underwritten offering, selling 18 million common shares at $1.00 each to raise approximately $18 million in gross proceeds. Net proceeds of about $16.8 million are earmarked for working capital and general corporate purposes. The of", "url": "https://www.tradingview.com/news/tradingview:b3e6d93a865c3:0-lucid-diagnostics-closes-18m-underwritten-offering-issues-18m-shares-at-1-00/", "source_name": "TradingView", "published_at": "2026-04-24T20:09:18", "published_display": "24 Apr 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by a $15M investor, Lucid closes $18M share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbGx5eHRKNWMwb3ZzOXJXZzdsckhkQk9MMlBIVkF0bTN0V0Znb0lWNTVwYU9sT2NndXdfaS1vZlZ0NDJsak1zTlpZdXNBa1NKRnNxWUkyMG01M1VKMHRFRmNvN3ozMVBpYW5Hb0FrREJ5LVRvM1p1QTh1NUpza2s5Tzc5czFSQWl0bFVmOHAtQ1hZdjBhVEZPWXFpX3F5MUtLSFczbW9iQm9NNUhtMnVXUFoxUGRpNUxi?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNdGx5U3d2SVJwMklKU1ZHRkFtMDRyNmUzNTUtNGpUc19lSXkteVdBWDZaT1RiWGxsdTNBb3NsQ0FDbUVfWUk3cGxGQk5lOUdqV0w5VjNQUTRNWG9CcnpwV1F5d3hBc0pMb25VNlExRHdHMFl2c2tUSndXRGMyaTBnWGp4M29rNkNyZURlRzNEMm43WUh0UUdUbkVkekp4T215V1ZzLXVMTHNvVFoyRzlPNVJ6R21NRFVRNnpuVTZSUHZyUl9vd213Z3pEeEo?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics (Nasdaq: LUCD) prices $18M underwritten stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOUTV1XzY3Q29hOThsY2ZJYmhpRlBKcHZYbDFiMWpDM0U3UHo0bUtQQ3NHLW5HMFVzbFhwNnhUWkpWNjRYdXJsSGJxTVFXVGhoT1lGd0lMVHBoQXV1Y2M1OGp6c3hodHYxcHFUdTV0TTdqSF9zY2M0N2xkRU94SWxOVW5Yd2oyT0JzUXZsVEtxTnNHU1J2ZGJRRmlKeC1XazQ4ZnBoai16ZEI2MkVhcWI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A $15M anchor investor backs Lucid\u2019s 18M-share stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNVWZkSGR3LUY5VXpmc3dPRExoWTQ2cnBSbHNNbUpxMHJzYWdHR29pTkFfbGFRZFp0eVJCT0hGNFFpYzFtSDVDQzZVQzJFN2U4elptQ3YybEtxV2JQemxrRjd6YWtPSjR5RFhVYnVVZTctZjAwWUpSUVZqUTE2cG1scDJzLUNBNWJaSFgtUFJjWGxuazY5OWExQk1ydEQxTmktcEt6MVpKUzY3NXN5MlNFdVp0OG51ODFndWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Prices $18 Million Underwritten Offering at $1 Per Share With Canaccord and BTIG", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxOb1FUaWpwVVVYWFRhY1B4X0otZEZYSjU1UzlWUWRYd3gyc0FnOUpWck93d0c0WTRWMGJyTUxQaldfbnV5MUFCLUlCMUE3bDEwcEt2OVFMN3N6T3BXbjJoOUg0dkg3a0VSWUloeXVsX2RpTTU4MGpvTS14LWp1TmdsWDFpRkVZRmZodkhqMWFTY3h4Tkd2VElGenZPU2VneVI2Q21tWnUzTlF5SU9OeDVKMXFpcDZHZHFEdUdJN3lKTnB4UTJxd2xGZkF2RzQ4ME11NzJLaGh2Ni1FVWtjYy1jMVNibDJ4QWd1TUJKaHNRaw?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG reiterates Lucid Diagnostics stock rating on Q4 beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQWS1Xem8wWkVNZk50OE51bnVvUnNicmtPemtNZjNNUDhKNEhyTU5UY3VsS1VQdFd3VXl5QmZIejhRNlhaY3pUNzFDVGx2NHlPREdrN0tMbDJCM1pkT0hkcVdOSUx2UjZqTERnV2VnT2xLc3dnWlZIOXJpa29BcGFkZHNMLS1ZWkRkQlJweWVwaU1sZkZqZGx5S1dxcFNxT0d6d2hMX1hpU21qSzdoYWptR1dhaXRvbnNn?oc=5", "source_name": "Investing.com", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNaXgtTEYyZmZQcVV5c2pwX0Q1b1JETHdBaU5PdlI2eXEyejlGYUlQenZPdzdCa29sYVF4WWpYUUlaSjZINTRQTGNkSnROS3p1T0I2YkJuMDJwcGFrd04zUXZ0c3NVb2g4blZBaEcySDZ2V2p4c3JXVGY5Y19rVTgtTUJ1dUR2RDJFMHNDTTJwTXpFMzBWWHZOZkEyOWExbGJHTWl3eVJhMUtranNlLXMxOFNHTDFiRmN1cDhCbW5OdzR5MktyNl9oanBzNGw2NTBDMzhZWVA0alVPYlVQWUdSYzhLNVcwUTdleHZScWFxUUwxeE54?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc. (LUCD) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPTnpEZEE3YUJUaG05TXdrWGh4T0x0NEUzTU9lMDNBZWNkcU52RWdwSU50QkI4RXhYSlBxdGJucXZOMERRY1ZFMU4yZWVFTW9KY0VBMWY4eVJpVFpiaDlsQVdUbkNkZEMzUGJmSXNfTWZCNDNTT2tsNERrLS11Y1M3dDRveXlydUZaWGxqTHVZcmZTMGlkXzlWN2xFLTJSS28?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & Supplies - Imaging, Diagnostics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxORnRwNHkwQmJ3Nl9famF1aktWdDdLV2ZfNjFCVm9WSFJrQTRSMURQUEJrMGtZUTFiVEtZWGxyUWwwai04Zk4wZ2pTWXFsLUozTzR2Ykd5UUREenZmSTRWdzJPODNONWFCWUVoVlBuTmtVSnpWQXFOVEVMdWNDLWNfRnRqRWdweElVS2pabQ?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard\u00ae", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNZUtIMy1XcDZqMVAwRER3VHU4cHE1MlhMMFZrdnp2Ty1YX3JwRXFJdzZfYk1lUUx1UHRUY3BOcVNRbWQ2SUR0WU9yNWtiazBNZ3U3cmZ5aXNVNXFwdVczUXNkZ3huMWVJckJKTTFTODdpU1BqVUZ1eTJleG14S3U0SklKaklFMURLQzJRZXZXN0xLZUFzZFlLcWwtZ1NtWEwwUVFzQjFBc3pEc3pfM3NqcnFJZmR4d09mN3UxMHpHbnBuOGJmQzg0NHczRnBkVVdNZHRZ?oc=5", "source_name": "PR Newswire", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PAVmed-unit Lucid Diagnostics spikes on VA contract (LUCD)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOVGkyQno5anU4TkRPQW03WWdXT1UtaWcxX3NGdnFVZlFINHE3clRtb3hpTFlxQVhxd1ZzNVd2bWNoY1NXblNQNTlCMXRRVkp4azh3TlkxV2Znb1BNWEw1Qm1fMHhnQ05RVXlXQTJYX01VendtNVZPc2FwUlIzbGExckJjbHhjNmM3cDJVUUYxdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VA taps Lucid's EsoGuard cancer test, opening access for 9M veterans", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOclVlT1FYNXBGcW5ROFhMX2luYnF6eEhHZmpjNkYzMG5oT3VtYllFeS0zUWM4YWFhRHQtNUFUQUdiS1JuTmZ2VktZa3o5SHJoMFY1aWphNkVFa3JyRmpBM1NHa0dlYTcyVXVwRklUamgyWVFrWTFyT3VVeWRUUzQta2hpRHFFX0VBMUVFNllGTllveHVROWJpb0EtMDZlX1ZzS2dlSF9EaFk4VFpQVkFfLU9NQXFFZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here\u2019s Why Lucid Diagnostics (LUCD) Declined in Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOcl81cGZ5STlSWFl2dGlBNEZjOVBJUThOeHFtb21JN0RuamhRczdSR2pOS0Qtd3NiSjFTTVhEQmctN1F0U2FUZDdiR1ZFQVlQdE0ydmhMMURyRUlUa2YtVEtNMDI3bWlrV29RTGpkRUQtMW5oUVFWMlRpVENBNno4UHBmVUlyN2FL?oc=5", "source_name": "Market source", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-13T08:00:00+00:00", "published_display": "13 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30%", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQa2pZaTdoTFg0V05OaFVGWEZ5Y1V6QXh4OVlhZ3M5ckk5ajJmdWtJanJBQml6LWg4ejd3WkNVZkV5REtCRl9oTjgwRUZtckFEdk95QXM3YnNRUXdEMW41UEtMSHJleEFVMmxvOGlmVzVQc3VvZGxITXF0clEwY3p0bVNFSkZlUQ?oc=5", "source_name": "Market source", "published_at": "2025-11-29T08:00:00+00:00", "published_display": "29 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T14:49:04+00:00", "published_display": "16 Jun 2026 14:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxOMV82Sjl0aF9hd3gxUmliWk5Jbk1nb01jcGRva1ByQm5JWVVMUWMzVkxqREwwam9pLWRWUldWa3pNOEJPRGtjSVpaRXlseFBlSVQxM2pSRm92NFBITXdVLVNRRm5fczFEcHFtNC1GTWVaLS1Lekp6dU1BdzJqWEtpZ0J3QmJIY0pxUlhaMGh3RzIyUGZ5SWo5QWJySzFUSnp4cVZTTVlCdjhHMld0dGVxbENub01kb0NfVVhnY2F5YzUwRUM5MU8xNmxoVXE4RTFxRnB2bFY4M1JzYlN0cDZJcDJxUnByS0ZEVC1IMU9CN3RQN0dsM09ucDhsdHdwUTZseklZcEdiWngtUm1GeEdUVUUxVF90SndQaEE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Baxter (NYSE:BAX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYjhBT3BjMWFVU1FFUUFub0d6QUVEUTdwWFVMRG5fN2dHSnIxTXQwMWU1aElKaEV1a2dYLTFHMlBzMVFTZEtaX0xRRDFhZDl1WFdDYWF2RDZxOG9SRUtycmZacTRzM2FaaEU3OS1GZ2taLWtSMjZ4enhVNHRvdzJsanp4cEhNcGI1dllTOUplWUUtNjRlRm85MlFEVWxSYUV2d243QVd3?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Specialty Stocks\u2019 Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQcXUxeEZpRzE0aXJ0RVlrVXZMdF9pSEV3VTROeDNWdjNZZWVDNVhKZU9BRFpIOWlZYzJrU1RZVzFDLUZhRDBjY0pBdVB2YVJUNVZvZEhubmd1OXlobFJaUWxVbUtlVEFwdWNVQnRqMDBHbEFubzBpczN1Zi1mN0xFbC1pTHpqZzA?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOb3BiQVNFREdNblk2QS10b1lhRUtfb05vU2VFZHB5V0hJT0R4NmhwQWRrcFVsR3UwMjZleFV6N2FEelpZVzY3YWFxSWE1cWpLaTFrQVU4NktkQUloUkxaV3ZTVkh6b1ZmaDdMN2ViX1BUNE4xUTNUZFNlR0syVGlZSg?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q3 Earnings: Inspire Medical Systems (NYSE:INSP) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOekhIMGs0UXlrdHhudkYzRWhSXzBNazdMLXBSTnd5dEFTZDR3MkdBc1AtNUNrcmp4Z1IxNVBuZVJJejdkdjdwT1Zoc0NudGMxVGNjRGxaUGVrYncxekxMNWV5RGlNNjZWUW9vdzdwaVRtTlMzcFl0MWRZNDlTY0xWWkNteE9fTU9LMm5aX1VuSll2UTNONzRqNnVpYXRvbDVIX1lXaGJMV3JKZFltUTVPNVpUc2Q0MHdYVUUydmZUMVo4dDIzLUxjZk53c1J1bDcxTXJWa0VNZXdJanZfbUVHcmgwamRwaGJyc1pXeGhtZ1dnaTJMN2JCeHlJLUFCZXRaVFhaUHozVi1wRlQ1dkE?oc=5", "source_name": "StockStory", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q3 Earnings Outperformers: Enovis (NYSE:ENOV) And The Rest Of The Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPTFZqejZjVDBJV2huRzViQmxXeEQ5SWc3aC1NN0RITkxhdlpCYjRSa0FUTDdtRXJzcWQ5UnJlQXY2QW11cGpKMGdGVGFiZGhrcm1UVnA0YUprNG1uQktqWnU0Ny1WTTcxcTIxZkJLNHJUcEU0aVl3Um8xTzhqQW5uREI1NU5qYUZTbkV4M3JPMzFvbW5TamdZcnphRlpubTNvOEJHSU9mcUhXdkpEVmJtNXRCUEtYTHZmT2NIbmQ1Wmpsb3doeFQxUERIQk5zYjJ0Vi1FR1ZDZ3lXdzlJSWRfa0VIR0xTYnJTWjRUUzJNblVyTld3Qm9B?oc=5", "source_name": "StockStory", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 64, "sentiment_summary": {"positive": 10, "negative": 4, "neutral": 50, "score": 52, "total": 64, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 79, "events": [{"event": "earnings", "label": "Earnings", "weight": 18.56, "count": 37}, {"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.45, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.08, "latest_week": "2026-06-19", "one_week_move": 12.4, "four_week_move": 0.9, "twelve_week_move": -3.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.722383, "market_dynamics_buy_signal": false, "relative_strength": -21.866807, "fair_value_gap": -5.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.1255, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.4% over one week, +0.9% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "MSN", "count": 3}, {"label": "StockStory", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 13}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 37}, {"label": "Market update", "count": 19}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.4% over one week, +0.9% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution"}], "updated_at": "2026-06-22T20:21:36.457078+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}